ArticleLangenbeck's archives of surgery2010
11C-metomidate positron emission tomography after dexamethasone suppression for detection of small adrenocortical adenomas in primary aldosteronism.
Article in Langenbeck's archives of surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Pooled it
- Emerging methods for subtype differentiation in primary aldosteronism.Journal of internal medicine · 2026Review
- Development of a CYP11B2 imaging tracer for primary aldosteronism: basic evaluation of iodine- and fluorine-incorporated pyridinyldihydroquinolinone derivatives.EJNMMI radiopharmacy and chemistry · 2025Article
- 2023 Korean Endocrine Society Consensus Guidelines for the Diagnosis and Management of Primary Aldosteronism.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- Advances in the molecular imaging of primary aldosteronism.Annals of nuclear medicine · 2023Review
- 3D printingEJNMMI physics · 2021Article
- Adrenal Incidentaloma.Endocrine reviews · 2020Review
- Steroid Profiling and Immunohistochemistry for Subtyping and Outcome Prediction in Primary Aldosteronism-a Review.Current hypertension reports · 2019Review
- Progress in the Management of Primary Aldosteronism.American journal of hypertension · 2018Review
- Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?International journal of molecular sciences · 2017Review
- NP-59 test for preoperative localization of primary hyperaldosteronism.Langenbeck's archives of surgery · 2017Article
- Targeted Molecular Imaging in Adrenal Disease-An Emerging Role for Metomidate PET-CT.Diagnostics (Basel, Switzerland) · 2016Review
- Nuclear medicine imaging in the evaluation of endocrine hypertension.Indian journal of endocrinology and metabolism · 2012Article
- Primary aldosteronism: from bench to bedside.Endocrine · 2012Review
- Imaging of adrenal masses with emphasis on adrenocortical tumors.Theranostics · 2012Article
- Metomidate-based imaging of adrenal masses.Hormones & cancer · 2011Review
- Surgical endocrinology--update 2010.Langenbeck's archives of surgery · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate whether dexamethasone suppression treatment can improve (11) C-metomidate positron emission tomography (MTO-PET) detection of small adrenocortical adenomas in primary aldosteronism (PA). MATERIALS AND
methodsEleven patients with proven PA and two patients with non-hyperfunctioning adrenocortical incidentalomas and small adrenocortical tumours observed on CT underwent MTO-PET before and 3 days after administration of oral dexamethasone suppression treatment. Small "hot-spot" regions of interest comprising 4 pixels (SUVhs) and 1 pixel (SUVmax) were placed in the tumour area with the highest radioactivity concentration and their respective standardised uptake values (SUV) were recorded.
resultsAll tumours were detected and categorised as adrenocortical by MTO-PET. SUVhs as well as SUVmax were higher in PA compared to nonfunctional adenomas. Normal adrenal cortex was suppressed after dexamethasone (p < 0.05), but tumour SUV was not significantly decreased after suppression in either PA or nonfunctional tumours (p > 0.05). However, these changes caused no significant increase in the tumour-to-normal adrenal ratio (p > 0.05).
conclusionMTO-PET is a highly sensitive method for detecting and categorising even small adrenocortical tumours in PA. In this series, dexamethasone-suppressed MTO-PET was unable to increase the tumour-to-normal adrenal ratio to further facilitate detection of small adenomas in PA as an alternative to adrenal venous sampling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.